Atlas of Genetics and Cytogenetics in Oncology and Haematology

Home   Genes   Leukemias   Solid Tumours   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

X Y 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 NA
Taking over the Atlas
Dear Colleagues,
The Atlas, once more, is in great danger, and I will have to proceed to a collective economic lay-off of all the team involved in the Atlas before the begining of April 2015 (a foundation having suddenly withdrawn its commitment to support the Atlas). I ask you herein if any Scientific Society (a Society of Cytogenetics, of Clinical Genetics, of Hematology, or a Cancer Society, or any other...), any University and/or Hospital, any Charity, or any database would be interested in taking over the Atlas, in whole or in part. If taking charge of the whole lot is too big, a consortium of various actors could be the solution (I am myself trying to find partners). Could you please spread the information, contact the relevant authorities, and find partners.
Survival of the Atlas will be critically dependant upon your ability to find solutions (and urgently!).
Kind regards.
Jean-Loup Huret
Donations are also welcome
If each casual visitor gives 3 Euros or Dollars, the Atlas is saved in a week !
If each professional gives 100 Euros or Dollars once a year (now), the Atlas is saved in 2 weeks !
Don't let the Atlas imminent demise
Note: we send fiscal receipts for donations equal or above 50 Euros or Dollars

Donate (in Euros)

Donate (in US Dollars)

FXYD5 (FXYD domain containing ion transport regulator 5)


Other namesDYSAD
LocusID (NCBI) 53827
Location 19q13.12
Location_base_pair Starts at 35645845 and ends at 35660788 bp from pter ( according to hg19-Feb_2009)  [Mapping]


Transcription 0.9 kb mRNA; 534 bp open reading frame.


  Dysadherin protein consists of 178 amino acids.
Description The deduced amino acid sequence consisted of two hydrophobic regions corresponding to a signal peptide and a transmembrane domain (146-162), a serine-, threonine-, and proline-rich extracellular domain, which is a target for O-glycosylation, anda short cytoplasmic region containing positively charged amino acid residues.
Expression Endothelial cell, T lymphocytes, basal cell of squamous epithelium.
Localisation Cell membrane
Homology The transmembrane domain of dysadherin and mouse RIC especially showed a very high degree of similarity to other ion channels such as Mat-8 chloride channel, phospholemman, which is the major plasma membrane substrate for cAMPdependent protein kinase and protein kinase C, and the subunit of Na, K-ATPase.

Implicated in

Entity Various cancers
Disease Dysadherin, newly identified cell membrane glycoprotein, downregulates E-cadherin and promotes cancer invasion and metastasis. A reverse correlation between dysadherin expression and E-cadherin expression was observed in various cancers. Increased dysadherin expression was correlated with poor prognosis with head and neck squamous cell carcinoma, esophageal carcinoma, gastric carcinoma, colorectal carcinoma, melanoma and so on. Dysadherin expression in epitheloid sarcomas could be a used as powerful diagnostic marker for distinguishing epithelioid sarcomas from malignant rabdoid tumors.

External links

HGNC (Hugo)FXYD5   4029
Entrez_Gene (NCBI)FXYD5  53827  FXYD domain containing ion transport regulator 5
GeneCards (Weizmann)FXYD5
Ensembl hg19 (Hinxton)ENSG00000089327 [Gene_View]  chr19:35645845-35660788 [Contig_View]  FXYD5 [Vega]
Ensembl hg38 (Hinxton)ENSG00000089327 [Gene_View]  chr19:35645845-35660788 [Contig_View]  FXYD5 [Vega]
ICGC DataPortalENSG00000089327
Genatlas (Paris)FXYD5
SOURCE (Princeton)FXYD5
Genomic and cartography
GoldenPath hg19 (UCSC)FXYD5  -     chr19:35645845-35660788 +  19q13.12   [Description]    (hg19-Feb_2009)
GoldenPath hg38 (UCSC)FXYD5  -     19q13.12   [Description]    (hg38-Dec_2013)
EnsemblFXYD5 - 19q13.12 [CytoView hg19]  FXYD5 - 19q13.12 [CytoView hg38]
Mapping of homologs : NCBIFXYD5 [Mapview hg19]  FXYD5 [Mapview hg38]
Gene and transcription
Genbank (Entrez)AA044211 AA296696 AB072911 AF161462 AF177940
RefSeq transcript (Entrez)NM_001164605 NM_014164 NM_144779
RefSeq genomic (Entrez)NC_000019 NC_018930 NT_011109 NW_004929415
Consensus coding sequences : CCDS (NCBI)FXYD5
Cluster EST : UnigeneHs.333418 [ NCBI ]
CGAP (NCI)Hs.333418
Alternative Splicing : Fast-db (Paris)GSHG0014822
Alternative Splicing GalleryENSG00000089327
Gene ExpressionFXYD5 [ NCBI-GEO ]     FXYD5 [ SEEK ]   FXYD5 [ MEM ]
SOURCE (Princeton)Expression in : [Normal Tissue Atlas]  [carcinoma Classsification]  [NCI60]
Protein : pattern, domain, 3D structure
UniProt/SwissProtQ96DB9 (Uniprot)
NextProtQ96DB9  [Medical]
With graphics : InterProQ96DB9
Splice isoforms : SwissVarQ96DB9 (Swissvar)
Domaine pattern : Prosite (Expaxy)FXYD (PS01310)   
Domains : Interpro (EBI)Ion-transport_regulator_FXYD   
Related proteins : CluSTrQ96DB9
Domain families : Pfam (Sanger)ATP1G1_PLM_MAT8 (PF02038)   
Domain families : Pfam (NCBI)pfam02038   
Domain structure : Prodom (Prabi Lyon)PD005989 (PD005989)   
DMDM Disease mutations53827
Blocks (Seattle)Q96DB9
Human Protein AtlasENSG00000089327
Peptide AtlasQ96DB9
IPIIPI00419588   IPI00220419   IPI00909621   IPI00789942   
Protein Interaction databases
IntAct (EBI)Q96DB9
Ontologies - Pathways
Ontology : AmiGOactin binding  ion channel activity  integral component of plasma membrane  integral component of membrane  sodium channel regulator activity  microvillus assembly  ion transmembrane transport  cadherin binding  negative regulation of calcium-dependent cell-cell adhesion  regulation of sodium ion transmembrane transporter activity  
Ontology : EGO-EBIactin binding  ion channel activity  integral component of plasma membrane  integral component of membrane  sodium channel regulator activity  microvillus assembly  ion transmembrane transport  cadherin binding  negative regulation of calcium-dependent cell-cell adhesion  regulation of sodium ion transmembrane transporter activity  
Protein Interaction DatabaseFXYD5
DoCM (Curated mutations)FXYD5
Wikipedia pathwaysFXYD5
Gene fusion - rearrangements
Polymorphisms : SNP, variants
NCBI Variation ViewerFXYD5 [hg38]
dbSNP Single Nucleotide Polymorphism (NCBI)FXYD5
Exome Variant ServerFXYD5
Genetic variants : HAPMAPFXYD5
Genomic Variants (DGV)FXYD5 [DGVbeta]
ICGC Data PortalENSG00000089327 
Somatic Mutations in Cancer : COSMICFXYD5 
CONAN: Copy Number AnalysisFXYD5 
LOVD (Leiden Open Variation Database)Whole genome datasets
LOVD (Leiden Open Variation Database)LOVD - Leiden Open Variation Database
LOVD (Leiden Open Variation Database)LOVD 3.0 shared installation
Impact of mutations[PolyPhen2] [SIFT Human Coding SNP] [Buck Institute : MutDB] [Mutation Assessor] 
DECIPHER (Syndromes)19:35645845-35660788
Mutations and Diseases : HGMDFXYD5
NextProtQ96DB9 [Medical]
Disease Genetic AssociationFXYD5
Huge Navigator FXYD5 [HugePedia]  FXYD5 [HugeCancerGEM]
snp3D : Map Gene to Disease53827
DGIdb (Drug Gene Interaction db)FXYD5
General knowledge
Homologs : HomoloGeneFXYD5
Homology/Alignments : Family Browser (UCSC)FXYD5
Phylogenetic Trees/Animal Genes : TreeFamFXYD5
Chemical/Protein Interactions : CTD53827
Chemical/Pharm GKB GenePA28445
Clinical trialFXYD5
Cancer Resource (Charite)ENSG00000089327
Other databases
PubMed36 Pubmed reference(s) in Entrez


Dysadherin, a cancer-associated cell membrane glycoprotein, down-regulates E-cadherin and promotes metastasis.
Ino Y, Gotoh M, Sakamoto M, Tsukagoshi K, Hirohashi S.
Proc Natl Acad Sci USA. 2002; 99(1): 365-70.
PMID 11756660
Prognostic significance of dysadherin expression in advanced colorectal carcinoma.
Aoki S, Shimamura T, Shibata T, Nakanishi Y, Moriya Y, Sato Y, Kitajima M, Sakamoto M, Hirohashi S.
Br J Cancer. 2003; 88(5): 726-32.
PMID 12618882
Cell adhesion system and human cancer morphogenesis.
Hirohashi S, Kanai Y.
Cancer Sci. 2003; 94(7): 575-81. (Review)
PMID 12841864
Dysadherin: expression and clinical significance in thyroid carcinoma.
Sato H, Ino Y, Miura A, Abe Y, Sakai H, Ito K, Hirohashi S.
J Clin Endocrinol Metab. 2003; 88(9): 4407-12.
PMID 12970317
Dysadherin overexpression in pancreatic ductal adenocarcinoma reflects tumor aggressiveness: relationship to E-cadherin expression.
Shimamura T, Sakamoto M, Ino Y, Sato Y, Shimada K, Kosuge T, Sekihara H, Hirohashi S.
J Clin Oncol. 2003; 21(4): 659-67.
PMID 12586803
Aberrant O-glycosylation inhibits stable expression of dysadherin, a carcinoma-associated antigen, and facilitates cell-cell adhesion.
Tsuiji H, Takasaki S, Sakamoto M, Irimura T, Hirohashi S.
Glycobiology. 2003; 13(7): 521-7.
PMID 12672699
Prognostic significance of dysadherin expression in tongue cancer: immunohistochemical analysis of 91 cases.
Nakanishi Y, Akimoto S, Sato Y, Kanai Y, Sakamoto M, Hirohashi S.
Appl Immunohistochem Mol Morphol. 2004; 12(4): 323-8.
PMID 15536331
Prognostic significance of dysadherin expression in esophageal squamous cell carcinoma.
Shimada Y, Hashimoto Y, Kan T, Kawamura J, Okumura T, Soma T, Kondo K, Teratani N, Watanabe G, Ino Y, Sakamoto M, Hirohashi S, Imamura M.
Oncology. 2004; 67(1): 73-80.
PMID 15459499
Clinical significance of dysadherin expression in gastric cancer patients.
Shimada Y, Yamasaki S, Hashimoto Y, Ito T, Kawamura J, Soma T, Ino Y, Nakanishi Y, Sakamoto M, Hirohashi S, Imamura M.
Clin Cancer Res. 2004; 10(8): 2818-23.
PMID 15102690
Dysadherin expression facilitates cell motility and metastatic potential of human pancreatic cancer cells.
Shimamura T, Yasuda J, Ino Y, Gotoh M, Tsuchiya A, Nakajima A, Sakamoto M, Kanai Y, Hirohashi S.
Cancer Res. 2004; 64(19): 6989-95.
PMID 15466191
Prognostic significance of dysadherin expression in cervical squamous cell carcinoma.
Wu D, Qiao Y, Kristensen GB, Li S, Troen G, Holm R, Nesland JM, Suo Z.
Pathol Oncol Res. 2004; 10(4): 212-8.
PMID 15619642
Establishment of two cell lines from human gastric scirrhous carcinoma that possess the potential to metastasize spontaneously in nude mice.
Yanagihara K, Tanaka H, Takigahira M, Ino Y, Yamaguchi Y, Toge T, Sugano K, Hirohashi S.
Cancer Sci. 2004; 95(7): 575-82.
PMID 15245593
Clinicopathologic significance of dysadherin expression in cutaneous malignant melanoma: immunohistochemical analysis of 115 patients.
Nishizawa A, Nakanishi Y, Yoshimura K, Sasajima Y, Yamazaki N, Yamamoto A, Hanada K, Kanai Y, Hirohashi S.
Cancer. 2005; 103(8): 1693-700.
PMID 15751018
Prognostic significance of dysadherin expression in patients with non-small cell lung cancer.
Tamura M, Ohta Y, Tsunezuka Y, Matsumoto I, Kawakami K, Oda M, Watanabe G.
J Thorac Cardiovasc Surg. 2005; 130(3): 740-5.
PMID 16153922
Expression patterns of dysadherin and E-cadherin in lymph node metastases of colorectal carcinoma.
Batistatou A, Charalabopoulos AK, Scopa CD, Nakanishi Y, Kappas A, Hirohashi S, Agnantis NJ, Charalabopoulos K.
Virchows Arch. 2006; 448(6): 763-7.
PMID 16570180
Prognostic significance of dysadherin expression in epithelioid sarcoma and its diagnostic utility in distinguishing epithelioid sarcoma from malignant rhabdoid tumor.
Izumi T, Oda Y, Hasegawa T, Nakanishi Y, Iwasaki H, Sonobe H, Goto H, Kusakabe H, Takahira T, Kobayashi C, Kawaguchi K, Saito T, Yamamoto H, Tamiya S, Iwamoto Y, Tsuneyoshi M.
Mod Pathol. 2006; 19(6): 820-31.
PMID 16557275
Dysadherin expression in head and neck squamous cell carcinoma: association with lymphangiogenesis and prognostic significance.
Kyzas PA, Stefanou D, Batistatou A, Agnantis NJ, Nakanishi Y, Hirohashi S, Charalabopoulos K.
Am J Surg Pathol. 2006; 30(2): 185-93.
PMID 16434892
Chemokine (C-C motif) ligand 2 mediates the prometastatic effect of dysadherin in human breast cancer cells.
Nam JS, Kang MJ, Suchar AM, Shimamura T, Kohn EA, Michalowska AM, Jordan VC, Hirohashi S, Wakefield LM.
Cancer Res. 2006; 66(14): 7176-84.
PMID 16849564
Expression of dysadherin and E-cadherin in trophoblastic tissue in normal and abnormal pregnancies.
Batistatou A, Makrydimas G, Zagorianakou N, Zagorianakou P, Nakanishi Y, Agnantis NJ, Hirohashi S, Charalabopoulos K.
Placenta. 2007; 28(5-6): 590-2.
PMID 17084448
In breast carcinoma dysadherin expression is correlated with invasiveness but not with E-cadherin.
Batistatou A, Peschos D, Tsanou H, Charalabopoulos A, Nakanishi Y, Hirohashi S, Agnantis NJ, Charalabopoulos K.
Br J Cancer. 2007; 96(9): 1404-8.
PMID 17437014
Nuclear targeting of the growth hormone receptor results in dysregulation of cell proliferation and tumorigenesis.
Conway-Campbell BL, Wooh JW, Brooks AJ, Gordon D, Brown RJ, Lichanska AM, Chin HS, Barton CL, Boyle GM, Parsons PG, Jans DA, Waters MJ.
Proc Natl Acad Sci U S A. 2007; 104(33): 13331-6.
PMID 17690250
Dysadherin expression as a significant prognostic factor and as a determinant of histologic features in synovial sarcoma: special reference to its inverse relationship with E-cadherin expression.
Izumi T, Oda Y, Hasegawa T, Nakanishi Y, Kawai A, Sonobe H, Takahira T, Kobayashi C, Yamamoto H, Tamiya S, Hirohashi S, Iwamoto Y, Tsuneyoshi M.
Am J Surg Pathol. 2007; 31(1): 85-94.
PMID 17197923
Dysadherin: a new player in cancer progression.
Nam JS, Hirohashi S, Wakefield LM.
Cancer Lett. 2007; 255(2): 161-9. (Review)
PMID 17442482
REVIEW articlesautomatic search in PubMed
Last year publicationsautomatic search in PubMed

Search in all EBI   NCBI


Written07-2008Setsuo Hirohashi
Pathology Division, National Cancer Center Research Institute 5-1-1, Tsukiji, Chuo-ku, Tokyo 104-0045, Japan


This paper should be referenced as such :
Hirohashi, S
FXYD5 (FXYD domain containing ion transport regulator 5)
Atlas Genet Cytogenet Oncol Haematol. 2009;13(6):413-414.
Free journal version : [ pdf ]   [ DOI ]

© Atlas of Genetics and Cytogenetics in Oncology and Haematology
indexed on : Sat Mar 28 12:36:14 CET 2015

Home   Genes   Leukemias   Solid Tumours   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

For comments and suggestions or contributions, please contact us